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embodiments, the levels of the one or more biomarkers in the

BOMARKERS USED TO DETECT AND
MONITORNEUROLOGICAL AUTOMMUNE
DISEASES
CROSS REFERENCE TO RELATED
APPLICATIONS

This application claims the priority of benefit to U.S. appli
cation Ser. No. 61/680,938 filed on Aug. 8, 2012. The previ
ous application is incorporated herein in its entirety.
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FEDERALLY SPONSORED RESEARCHOR
DEVELOPMENT

This invention was made with government Support under
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Grant Nos. R21 AI081154, RRO15468, and P20 RR017675

awarded by the National Institutes of Health. The government
has certain rights in the invention.
TECHNICAL FIELD

This disclosure generally relates to biomarkers for neuro
logical autoimmune diseases and methods of using Such
biomarkers.

25

BACKGROUND

patient’s urine are compared to a standardized control.
In another aspect, a method of determining whether a com
pound is effective for treating a Subject having a neurological
autoimmune disease is provided. Such a method typically
includes collecting a first urine sample from a Subject; deter
mining the levels of one or more biomarkers in the first urine
sample, wherein the one or more biomarkers are selected
from the group consisting of 3-ureidopropionic acid, guani
dinoacetate and indoxyl Sulfate; administering a compound to
the Subject; collecting a second urine sample from the Sub
ject; and determining the levels of one or more of the biom
arkers in the secondurine sample. Generally, a decrease in the
level of one or more biomarkers in the secondurine sample
relative to the first urine sample is indicative of a compound
that is effective for treating a subject having a neurological
autoimmune disease. In one embodiment, the neurological
autoimmune disease is multiple Sclerosis.
In some instances, the Subject is a non-human animal. In
Some instances, the Subject is a human.
In some embodiments, the biomarkers are 3-ureidopropi
onic acid and guanidinoacetate. In some embodiments, the
biomarkers are 3-ureidopropionic acid and indoxyl Sulfate. In
Some embodiments, the biomarkers are guanidinoacetate and
indoxyl Sulfate. In some embodiments, the biomarkers are
3-ureidopropionic acid, guanidinoacetate and indoxyl Sul
fate. The levels of the one or more biomarkers can be deter

Autoimmune diseases arise from an inappropriate immune
response by the body against Substances or tissues normally
found in the body. Neurological autoimmune diseases are
those autoimmune diseases that affect some aspect of the
neurological system (e.g., the central nervous system or the
peripheral nervous system). Biomarkers of one or more neu
rological autoimmune diseases, especially those biomarkers
that can be evaluated non-invasively, are useful in the art.

30

Unless otherwise defined, all technical and scientific terms

35

40

vided.

In one aspect, a method of determining if a patient is
Suffering from, or is at risk of Suffering from, a neurological
autoimmune disease is provided. Such a method includes
collecting a urine sample from a patient; and determining the
levels of one or more biomarkers in the patient’s urine,

45

50

Part A: Preliminary Experiments and Results
FIG. 1A shows the urine metabolites that are upregulated/
downregulated in EAE mice. EAE was induced in C57B1/6
mice using MOG 35-55 in CFA and urine samples were
obtained from EAE mice that scored 3 to 4 and age-matched
healthy mice on day 17 post-immunization. The samples
were subjected to 2D 1H-13C HSQC NMR spectroscopy
analysis and the data were analyzed to compare the compo
sition of metabolites in EAE versus the control as described

55
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fate. The levels of the one or more biomarkers can be deter

mined, for example, using an immunoassay, chromatography,
spectroscopy or NMR.
In some embodiments, the levels of the one or more biom

arkers in the patient’s urine are compared to the levels of the
one or more biomarkers in a control patient that does not
Suffer from a neurological autoimmune disease. In some

below. In addition, the materials, methods, and examples are
illustrative only and not intended to be limiting. All publica
tions, patent applications, patents, and other references men
tioned herein are incorporated by reference in their entirety.
DESCRIPTION OF DRAWINGS

wherein the one or more biomarkers are selected from the

group consisting of 3-ureidopropionic acid, guanidinoacetate
and indoxyl sulfate. Generally, an increase in the level of the
one or more biomarkers in the patient’s urine is indicative of
the presence of a neurological autoimmune disease in the
patient. A representative neurological autoimmune disease is
multiple Sclerosis.
In some embodiments, the biomarkers are 3-ureidopropi
onic acid and guanidinoacetate. In some embodiments, the
biomarkers are 3-ureidopropionic acid and indoxyl Sulfate. In
Some embodiments, the biomarkers are guanidinoacetate and
indoxyl Sulfate. In some embodiments, the biomarkers are
3-ureidopropionic acid, guanidinoacetate and indoxyl Sul

used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which the methods and
compositions of matter belong. Although methods and mate
rials similar or equivalent to those described herein can be
used in the practice or testing of the methods and composi
tions of matter, suitable methods and materials are described

SUMMARY

Biomarkers of neurological autoimmune diseases are pro
vided, and methods of using Such biomarkers also are pro

mined, for example, using an immunoassay, chromatography,
spectroscopy or NMR.

65

herein. The urine metabolites are represented on the x-axis
and the fold difference on the y-axis. The metabolites with a
positive difference are those that have a greater presence in
EAE mice, and the metabolites with a negative difference are
those that have a greater presence in control mice. FIGS.
1(B)-(G) are graphs showing the overall results broken down
by organic acids (FIG. 1B), amino acids (FIG. 1C), carbohy
drates (FIG.1D), microbial products (FIG.1E), amines (FIG.
1F), and alcohols, ketones and aldehydes (FIG. 1G).
FIG. 2 is a schematic showing the metabolite pathway
network developed from the results shown in FIG. 1.
Part B: NMR Metabolomics-Based Analysis of Urine

FIG. 3 is a graph showing the 1D H-NMR spectrum of

healthy, diseased and treated mice.

US 9,304,123 B2
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FIG.4, Panel (A) is the 2DOPLS-DA score plot analysis of
healthy (dark Square), Saline injected (5-point star), CFA
injected (dark pentagon), diseased (large Sun-shaped star),
healthy treated with fingolimod (light square), CFA injected
mice treated with fingolimod (light circle), and diseased mice
treated with fingolimod (dark circle). Panel (B) is a metabo
lomics tree diagram based on the 2D OPLS-DA score plot of
Panel (A).
FIG. 5 is an OPLS-DA S-plot for urine collected from
healthy, saline-injected, CFA-injected, EAE mice (diseased),
healthy mice treated with Fingolimod, CFA-injected mice
treated with Fingolimod, and diseased mice treated with Fin
golimod.
FIG. 6 is a bar graph of metabolites up- or down-regulated
in the urine of EAE mice. GA (guanidoacetic acid), OA
(oxoglutaric acid), UN2 (unknown 2), ISU (indoxylsulfate),
UDPA (ureidopropionic acid), MG (methylguanidine), NGA
(N-acetylglutamic acid), PA (pimelic acid), NAP
(N-acetylputrescine), GAD (glyceraldehyde), NAK (N6
acetylysine), TMA (trimethylamine), AGM (agmatine),
MET (methionine), and UN1 (unknown 1).
Like reference symbols in the various drawings indicate

4
research as animal models. Those skilled in the art would

5
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Neurological autoimmune diseases such as multiple scle
rosis (MS) are very challenging diseases to properly diag
nose, and misdiagnosis is common. The diagnosis of MS
typically uses the McDonald criteria (McDonald et al., 2001,

30

Ann. Neurol., 50:121-7. Polman et al., 2005, Ann. Neurol.,

35

40

45

tiveness or efficacy of a compound (e.g., a drug) for treating
50

55

mediates in the metabolism of amino acids and nucleic acids,

respectively, and have been shown to be associated with neu
rological diseases (Kolker et al., 2001, J. Neurosci. Res.,
66:666-673; Neu et al., 2002, Neurobiol. Dis., 11:298–307),
but not necessarily neurological diseases with an autoim
mune component. All three biomarkers are statistically sig
nificantly down-regulated in an animal model of Suffering
from a neurological autoimmune disease similar to MS.
Animals having an existing or induced disease or injury
that is similar to a human condition are used routinely in

arkers in the patient. A control can be a sample from a control
patient that does not suffer from a neurological autoimmune
disease or from MS in which the level of the respective
biomarker(s) is determined. Additionally or alternatively, a
control can refer to a number or range of numbers that has
been standardized to the level of the respective biomarker(s)
in one or more control patients or a control population.
The methods described herein also can be used to deter

biomarkers identified hereincan be used to evaluate the effec

One of the biomarkers, indoxyl sulfate (Human Metabo
lome Database (HMDB) 00682), is a dietary protein metabo
lite and also is a metabolite of the amino acid, tryptophan. In
addition, indoxyl Sulfate strongly decreases the levels of glu
tathione, which is one of the most active antioxidant systems
of the cell. The other biomarkers, guanidinoacetate (HMDB
00128) and 3-ureidopropionic acid (HMDB 00026), are inter

Thus, determining the level of one or more of these biom
akers in urine can be used to determine if a patient is Suffering
from or is at risk of suffering from a neurological autoimmune
disease. As described herein, a decrease (e.g., a statistically
significant decrease) in the level of one, two or three of the
biomarkers (e.g., 3-ureidopropionic acid, guanidinoacetate,
or indoxyl Sulfate; 3-ureidopropionic acid & guanidinoac
etate, 3-ureidopropionic acid & indoxyl Sulfate, or guanidi
noacetate & indoxyl Sulfate; or 3-ureidopropionic acid,
guanidinoacetate & indoxyl Sulfate) indicates the presence of
a neurological autoimmune disease (e.g., MS) in the patient.
As used herein, statistical significance refers to a p-value of
less than 0.05, e.g., a p-value of less than 0.025 or a p-value of
less than 0.01, using an appropriate measure of statistical
significance, e.g., a one-tailed two sample t-test.
It would be appreciated by those in the art that the levels of
the one or more biomarkers in the urine from a patient can be
compared to a control in order to determine whether or not
there is a decrease in the levels of one or more of the biom

Three different metabolites were identified in urine, each

Such a disease.

herein can be used in the diagnosis and evaluation of MS, the
methods described herein also can be used in the diagnosis
and evaluation of symptoms associated with other neurologi
cal autoimmune diseases.

DETAILED DESCRIPTION

of which can be used as a biomarker to detect or diagnose a
neurological autoimmune disease such as MS in a patient
Suspected of Suffering from Such a disease, or at risk of
suffering from such a disease. Similarly, any of the three

sidered to be an animal model of MS because it exhibits

delayed onset; chronic-progressive course; relapsing-course;
and widespread lesions. See, for example, Steinman et al.,
2005, Trends Immunol., 26:565-71; and Steinman & Zamvil,
2006, Ann. Neurol., 60:12-21. While the methods described

like elements.

58:840-6), which relies on history, magnetic resonance imag
ing, visual evoked potentials, cerebrospinal fluid analysis and
hematology. Significant effort has been employed to identify
biomarkers from cerebrospinal fluid (CSF) to facilitate a
diagnosis for MS, but this endeavor has proven to be
extremely challenging and has not been Successful to date.
Additionally, there are associated risks with obtaining CSF
from patients. Therefore, a study was undertaken to investi
gate whether urine metabolites could be used as biomarkers
of MS and to evaluate the in vivo activity of MS drugs, given
that urine can be obtained non-invasively.

appreciate that rats, mice, guinea pigs, rabbits, and monkeys
can be induced to exhibit Experimental Autoimmune
Encephalomyelitis (EAE), which results in an animal model
exhibiting an autoimmune disease characterized by inflam
mation and demyelination of the central nervous system
(CNS) (Gold et al., 2006, Brain, 129:1953-71; Miller et al.,
2007, Curr: Prot. Immunol., Ch 15, Unit 15.1). EAE is con

60
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mine whether or not a compound is effective for treating a
Subject having a neurological autoimmune disease. For
example, urine can be collected at least one time before (e.g.,
a first urine sample) and at least one time after (e.g., a second
urine sample) a compound is administered to a subject. A
change in the level of a biomarker refers to the difference
between the level of the biomarker in the secondurine sample
and the level of the biomarker in the first urine sample and can
be expressed as the lack of a decrease in the level of the
biomarker (e.g., an increase or no change in the level of the
biomarker) or a decrease in the level of the biomarker.
In some embodiments, the Subject being administered the
compound is a human patient that is receiving a pharmaceu
tical composition (e.g., a drug), and the methods can be used
to monitor and evaluate the response of the patient to the
compound. For example, an increase in the level of any of the
biomarkers identified herein in the secondurine sample over
the first urine sample is an indication that the compound is
effective for treating a neurological autoimmune disease Such
as MS. On the other hand, a decrease in the level of any of the
biomarkers identified herein in the secondurine sample over

US 9,304,123 B2
6
lowing examples, which do not limit the scope of the methods
and compositions of matter described in the claims.

5
the first urine sample is an indication that the compound is not
effective for treating a neurological autoimmune disease Such
as MS.

EXAMPLES

In some embodiments, the Subject being administered the
compound can be a non-human animal (e.g., an animal
model, e.g., an EAE animal or a NOD mouse). A subject can
be administered a compound (e.g., a test compound) and the

Part A: Preliminary Experiments and Results
Example 1

level of one or more of the biomarkers described hereincan be

determined. These methods can be used, for example, to
screen compounds for their effectiveness in treating a subject
having a neurological autoimmune disease. As indicated
above, the lack of a decrease in the level of any of the biom
arkers identified herein in the second urine sample over the
first urine sample is an indication that the compound may be
effective for treating a neurological autoimmune disease
(e.g., MS), while a decrease in the level of any of the biom
arkers identified herein in the second urine sample over the
first urine sample is an indication that the compound likely is
not effective for treating a neurological autoimmune disease
(e.g., MS).
Compounds (e.g., test compounds) include, without limi
tation, nucleic acids (e.g., oligonucleotides), polypeptides
(e.g., enzymes, antibodies), chemical compounds, extracts
from bacteria, plant, fungi or animal cells, or mixtures
thereof. Such compounds can be administered to a subject
using any known means including, but not limited to, orally,
intravenously, intramuscularly, intraperitoneally, Subcutane
ously, intradermally, or topically.
As used herein, a compound that is effective for “treating
a patient or a subject refers to a compound that manages,
alleviates, ameliorates or remediates one or more symptoms
associated with a neurological autoimmune disease. The
symptoms associated with neurological autoimmune dis
eases are vastand include, simply by way of example, blurred
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Methods of collecting or expressing urine samples from
human patients or from animal Subjects are well known in the
art, as are methods of handling and storing urine samples.
45

using any number of methods. For example, immunoassays

literature. The invention will be further described in the fol

Sample Analysis

resonance Cryoprobe (H, C, "N) with a Z-axis gradient.
The 2D 'H-'C HSQC NMR data was collected using the

following parameters: 512 scans, 32 dummy Scan, 1.5 S relax
ation delay and with 64 fid size. All the spectra were pro
cessed using NMRPipe (see, for example, spinniddk.nih
.gov/NMRPipe?) and peak matching, and peak assignments
were performed using NMRView.J. Version 8.0 (see, for
example, the World Wide Web at onemoonscientific.com/
nmrview/summary.html) and chemical shift references from
the Human Metabolomics Database (HMDB) (see, for
example, hmdb.ca on the World Wide Web). The urinary
metabolites that are differentially excreted in controls and
EAE mice were noted and the metabolic intensities obtained
in EAE mice were subtracted from those of control mice to

are well known in the art and include, without limitation,

enzyme-linked immunosorbent assays (ELISAS), radioim
munoassays, Surround optical fiber immunoassay (SOFIA),
cloned enzyme donor immunoassay (CEDIA), or magnetic
immunoassay (MIA). The biomarkers described herein also
can be detected using, for example, liquid-chromatography
mass spectrometry (LC-MS); gas-chromatography-mass
spectrometry (GC-MS), liquid-chromatography-electro
chemistry array metabolomics platforms (LCECA), fourier
transform infrared spectroscopy (FTIR), capillary electro
phoresis electrospray ionization mass spectrometry (CE-ESI
MS), and ultra-performance liquid chromatography mass
spectrometry (UPLC-MS). In addition and as described
herein, the biomarkers can be detected in urine using NMR
(e.g., 1-dimensional (1D) or 2-dimensional (2D) NMR).
In accordance with the present invention, there may be
employed conventional molecular biology, microbiology,
biochemical, and recombinant DNA techniques within the
skill of the art. Such techniques are explained fully in the

25:1951-9). The animals were monitored for clinical signs of
EAE and scored until termination, which occurred on day 30
post-immunization (Miller et al., Supra; Mendel et al., Supra).
Urine samples were collected daily starting day -1 until day
30 from controls and mice with EAE showing bilateral hind
limb paralysis (scored 4). Three sample pools of 500 ul were
prepared for each group of mice and the Volumes were
brought up to 600 ul by adding 100 ul deuterium oxide (pH of
7.2) prior to NMR analysis.
Example 2

NMR experiments were conducted on urine samples col
lected from controls and EAE mice using Bruker AVANCE
DRX 500 MHz spectrometer equipped with 5 mm Triple

thereof.

The biomarkers described herein can be detected in urine

Groups of 5-to 6-week old female C57B 1/6 mice were
immunized with or without MOG 35-55 (MEVGWYRSPFS
RVVHLYRNGK (SEQ ID NO:1)) in complete Freund's
adjuvant (CFA; 200 ug/mouse) subcutaneously as described
(n=13 each) (Miller et al., 2007, Curr. Protoc. Immunol. Ch
15, Unit 15 11: Mendel et al., 1995, Eur: J. Immunol.,

or loss of vision, loss of coordination, loss of balance, loss of

bladder control, sexual dysfunction, fatigue, fever, numbness,
tingling and/or weakness of extremities, joint and/or muscle
aches, weight loss, hair loss, skin rash, and combinations

Sample Preparation

determine fold-change for each metabolite. The data are pre
50

55

60

sented in FIGS. 1 and 1A-1F.

FIG. 2 shows the pathway information for each of the
urinary metabolites that are differentially excreted in EAE
mice, which were obtained from the Kyoto Encylopedia of
Genes and Genomes (KEGG) (see, for example, genome.jp/
keg?kegg3a.html on the World Wide Web) and BioCyc (see
for example, biocyc.org on the WorldWideWeb). The urinary
metabolites were linked with the nearest possible metabolite
in the pathway.
Example 3
Summary of Preliminary Experiments and Results

65

The preliminary experiments above served to optimize the
conditions for determining metabolites in urine. The prelimi
nary results suggest that urine metabolites can be used to
predict disease progression in CNS autoimmune diseases. In

US 9,304,123 B2
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addition, the samples collected from individual animals on
days 16, 23 and 30 post-immunization were preserved as
separate aliquots.

7
addition, the urine metabolites can be used to evaluate the

efficacy of one or more drugs.
Part B: NMR Metabolomics-Based Analysis of
Urine

Example 8

Example 4

NMR Sample Preparation

Mice
10

Six to eight-week-old female C57B1/6 (H-2) mice were
obtained from the Jackson Laboratory (Bar Harbor, Me...). The
mice were maintained in accordance with the animal protocol
guidelines of the University of Nebraska-Lincoln, Lincoln,
Nebr.

For the 2D 'H-CHSQC experiments, 100 uL of a 50 mM

phosphate buffer in 99.8% DO (Isotec) at pH 7.2 (PBS,
uncorrected) were added to each 500 uL urine sample to a

final volume of 600 uL. For the 1D H NMR experiments, 600

15

uL of PBS was added to 10 uL of urine.
Example 9

Example 5

NMR Data Collection and Analysis

Peptide Synthesis and Immunization Procedures

NMR experiments were conducted with Bruker AVANCE
DRX 500 MHz spectrometer equipped with 5 mm Triple

MOG 35-55 peptide (SEQ ID NO:1) was synthesized on
9-fluorenylmethyloxy-carbonyl chemistry (Neopeptide,
Cambridge, Mass.) to a purity of more than 90% as verified by
HPLC and mass spectroscopy. The peptide was dissolved in

resonance Cryoprobe (H, C, "N) with a Z-axis gradient. A
BACS-120 sample changer with Bruker Icon software was

used to automate the NMR data collection. The 1D H NMR
25

data was collected at 298K with 32K data points, a spectrum
width of 5483 Hz 128 scan and 16 dummy scans using an

30

NMR data was collected at 298K with 512 scans, 32 dummy
scan and a 1.5 S relaxation delay. The spectrum was collected
with 2048K data points and a spectrum width of 4734 Hz in
the direct dimension and 64 data points and a spectrum width

1 xPBS, and stored at -20°C. until use.

excitation sculpting pulse sequence. The 2D 'H-'C HSQC

Example 6
Immunization and Treatment Procedures

of 18864 Hz, in the indirect dimension.

The experimental design consisted of seven treatment
groups (n=13). These include control, Saline, complete Fre
und's adjuvant (CFA) alone, EAE treatment (see below),
saline plus drug (Fingolimod), CFA plus drug, and EAE plus
drug. Each treatment group was divided into three batches,
each containing 4, 4 and 5 animals, respectively.
EAE treatment refers to the process of inducing experi
mental autoimmune encephalomyelitis (EAE) in mice, which
is a MS-like disease characterized by inflammation and
demyelination of the CNS. To induce EAE, peptide emul
sions were prepared by mixing MOG 35-55 (SEQID NO:1)
in CFA containing Mycobacterium tuberculosis H37RA
extract (Difco Laboratories, Detroit, Mich.) to a final concen
tration of 5 mg/ml. Each animal received 200 ug of peptide
emulsion Subcutaneously in the inguinal and sternal regions.
In addition, Pertussis toxin (List Biological Laboratories,
Campbell, Calif.) was administered (200ng per mouse) intra
peritoneally on day 0 and day 2 post immunization (Massila
many et al., 2010, J. Neuroimmunol., 219:17-24: Massila
many et al., 2011, J. Neuroimmunol., 230: 95-104;
Massilamany et al., 2011, BMC Immunol., 12:40). Seven
days post-immunization or in the no-injection control, fin
golimod was dissolved in normal saline to a working dilution
of 0.2 mg/ml, and administered intraperitoneally into the
animals corresponding to drug-treated groups as indicated
above at 1 mg/kg body weight daily until day 30.
Example 7

1D H NMR spectra were processed with the ACD/1D
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NMR manager version 12.0 (Advanced Chemistry Develop
ment, Inc.). After the residual water peaks were removed,
intelligent binning was used to integrate each region with a
bucket size of 0.025 ppm. The noise regions were removed by
changing the value of the bins to zero. Each NMR spectrum
was mean-centered and auto-scaled by the standard deviation
(Zhang et al., 2011, J. Proteome Res., 10:3743-54). Principal
component analysis (PCA), Orthogonal Partial List Square
Discreet Analysis (OPLS-DA) and S-plot were generated
using SIMCA P+12 (UMETRICS). The PCA2Tree software
was used to make the tree diagram (Werth et al., 2010, Ana
lytical Biochem., 399:56-63).

The 2D 'H-'C HSQC spectra were processed using

NMRPipe. Peak picking and peak matching were performed
using NMRView.JVersion 8.0. Peak intensities were normal
ized for each 2D NMR spectrum by dividing by the average
peak intensity for a given spectrum. Each peak for each
metabolite from each specific triplicate data set was further
normalized by the maximum intensity of the metabolite and
scaled to 100. The metabolite percent change was calculated
relative to the EAE group. Chemical shift references from the
Human Metabolomics Database were used to assign each
NMR peak to a metabolite (Wishart et al., 2009, Nuc. Acids
Res., 37:D603-10).
Example 10
Experimental Results

Urine Collection

Urine samples were collected both prior to and after dis
ease induction. The urine collections occurred three times

daily from each animal by expressing the bladder. The
samples collected from each batch of animals were pooled on
a daily basis and preserved at -80°C. until further analysis. In
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Evidence is presented that the NMR spectrum of urinary
metabolites can be used to diagnose MS by differentiating
between healthy mice, EAE-mice, and EAE-mice treated
with fingolimod, a drug recently approved for MS therapy.
Urine metabolites were evaluated by NMR spectroscopy
using an experimental design that consisted of seven treat

US 9,304,123 B2
ment groups: control, saline, complete Freund's adjuvant
(CFA), EAE, saline plus fingolimod, CFA plus fingolimod
and EAE plus fingolimod. FIG.3 shows the one-dimensional

(1D) H NMR spectra of urine obtained from healthy mice,
EAE-mice, and EAE-mice treated with fingolimod. A set of
NMR peaks (labeled B) are significantly increased in the
spectra for healthy mice relative to diseased mice. Con
versely, two sets of NMR peaks (labeled A and A') are
increased in the diseased mice spectrum relative to healthy
mice. These spectral differences correspond to a set of
metabolites that are differentially up-regulated and down
regulated in EAE-mice and are potential biomarkers for MS.
Additionally, the NMR spectra for the other control groups,
saline, Saline plus fingolimod or CFA plus fingolimod, were
essentially identical to the NMR spectra for the healthy mice.
It was next evaluated whether fingolimod would alter the
metabolomic profile of EAE-mice, consistent with its pre
dicted efficacy against MS. As expected, the urine metabo
lites observed in the NMR spectra for the EAE mice treated
with fingolimod resembled the NMR spectra for the healthy
mice (FIG.3). The spectral region B suppressed in EAE mice
has increased in intensity (labeled B"). Similarly, the spectral
regions A and A' have disappeared in EAE-mice treated with
fingolimod, shifting the metabolomics profiles towards the
healthy mice. To further quantitate the differences in the
metabolites obtained in healthy and EAE-mice, multivariate
statistical analysis techniques were used. A 2D plot from an
orthogonal partial least square discrete analysis (OPLS-DA)
revealed distinct clusters between the two groups (FIG. 4A).
As expected, control mice injected with saline, CFA and
fingolimod clustered together with the healthy mice. Notably,
the EAE mice treated with fingolimod were also clustered
with the controls. These results were further corroborated by
generating a metabolomics tree diagram (FIG. 4B). The high
boot-strap numbers (>50) indicate the statistical relevance of
each cluster or node.

An S-plot from the OPLS-DA is shown in FIG. 5. Each
point in the S-plot corresponds to a chemical shift range of
0.025 ppm or, more relevant, to a specific metabolite. The
point (metabolite) that significantly contributes to the class
cluster separation in the 2D scores plot are found at the
extremes (labeled) of the S-plot. The S-plot and NMR spectra
were compared to verify the spectral contributions to the class
separation between healthy and EAE mice. Points in the

5
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unknown aromatic metabolite also was observed, the concen
15

Example 11
Conclusions
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in vivo efficacy of potential drug-leads and designing patient
specific treatments.
The NMR analysis of urine by NMR takes approximately
10 minutes per sample and completely lacks any of the risks
or side effects associated with the analysis of other biological
samples, such as cerebrospinal fluid.
The lack of cure for MS and its increasing prevalence
amoung the population of young adults further emphasizes
the need to identify reliable markers of disease progression.
Thus, the NMR analysis of urine samples to evaluate the
metabolites identified herein holds the promise of being an
easy, fast, and safe diagnostic tool for MS.
It is to be understood that, while the methods and compo
sitions of matter have been described herein in conjunction
with a number of different aspects, the foregoing description
of the various aspects is intended to illustrate and not limit the
scope of the methods and compositions of matter. Other
aspects, advantages, and modifications are within the scope of
the following claims.
Disclosed are methods and compositions that can be used
for, can be used in conjunction with, can be used in prepara
tion for, or are products of the disclosed methods and com
positions. These and other materials are disclosed herein, and
it is understood that combinations, Subsets, interactions,

necessary because of the low natural abundance of C-la
beled metabolites. The 2D 'H-CHSQC spectra were com
pared between the two groups to identify the differences in
peak intensities. The NMR peaks were then assigned to
metabolites using Human Metabolomic Databases (hmdb.ca
on the World Wide Web). Metabolites are assigned based on
minimizing the chemical shift differences between the
experimental values reported herein and the values deposited
in the database, and maximizing the number of matching
chemical shifts. The identity of the metabolites that were up

It has been demonstrated herein that the metabolite com

position of urine samples differs between healthy and EAE
mice. Several key metabolites also have been identified that
are consistently down- or up-regulated in EAE-mice in com
parison with controls.
In addition, the metabolites can be used in the evaluation of

Urinary metabolites were further analyzed using 2D 'H-'

C HSQC spectra obtained from urine samples pooled from a
group of healthy or EAE mice. The use of pooled samples was

tration of which was relatively higher in EAE as compared to
healthy mice (FIG. 6). The detection of these structurally
uncharacterized metabolites provides new insights as to the
novel pathways that might be involved in EAE/MS pathogen
CS1S.

S-plot represented by triangles (A) were found to correlate

with NMR peaks in the previously identified A, A, B and B'
spectral regions in FIG. 3. These analyses validate the use of
NMR spectroscopy technology to assess urine metabolites as
indicators of disease progression in the EAE model.

10
or down-regulated in EAE-relative to healthy mice were plot
ted (FIG. 6). The analysis revealed that 3-ureidopropionic
acid (UDPA), guanidinoacetate (GA) and indoxyl sulfate
(ISU) were significantly down-regulated in the EAE mice,
thereby suggesting that any of these three metabolites can be
used as markers of a neurological autoimmune disorder.
Metformin, a drug used for diabetes mellitus, has been
shown to attenuate EAE progression in animal models (Nath
et al., 2009, J. Immunol., 182:8005-14). It was noted that a
NMR peak (UN 2 in FIG. 6) appears to have a structure
similar to metformin. It was postulated, therefore, that a met
formin-like metabolite might play a role in MS. A second

60
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groups, etc. of these methods and compositions are disclosed.
That is, while specific reference to each various individual
and collective combinations and permutations of these com
positions and methods may not be explicitly disclosed, each is
specifically contemplated and described herein. For example,
if a particular composition of matter or a particular method is
disclosed and discussed and a number of compositions or
methods are discussed, each and every combination and per
mutation of the compositions and the methods are specifically
contemplated unless specifically indicated to the contrary.

US 9,304,123 B2
11
Likewise, any Subset or combination of these is also specifi
cally contemplated and disclosed.
What is claimed is:

1. A method of monitoring the progression of EAE in a
rodent comprising:
collecting a urine sample from a rodent having EAE; and
determining the levels of one or more biomarkers in the
rodent's urine, wherein the one or more biomarkers

compromise 3-ureidopropionic acid;

wherein an increase in the level of the one or more biom

10

arkers in the rodent’s urine is indicative of the progres
2. The method of claim 1, wherein the one or more biom

arkers further comprise guanidinoacetate.

wherein a decrease in the level of one or more biomarkers
15

arkers further comprise indoxyl sulfate.

4. The method of claim 1, wherein the one or more biom

arkers further comprise guanidinoacetate and indoxyl Sulfate.

9. The method of claim 8, wherein the one or more biom

more biomarkers are determined using an immunoassay,
chromatography, spectroscopy or NMR.

10. The method of claim8, wherein the one or more biom

arkers further comprise indoxyl sulfate.

6. The method of claim 1, wherein the levels of the one or

11. The method of claim8, wherein the one or more biom

more biomarkers in the rodent’s urine are compared to the
7. The method of claim 1, wherein the levels of the one or

more biomarkers in the rodent’s urine are compared to a
standardized control.

in the second urine sample relative to the first urine
sample is indicative of a compound that is effective for
ameliorating the symptoms of EAE in a rodent.
arkers further comprise guanidinoacetate.

5. The method of claim 1, wherein the levels of the one or

levels of the one or more biomarkers in a control rodent that
does not suffer from EAE.

EAE; and

determining the levels of the one or more of the biomarkers
in the secondurine sample,

sion of EAE in the rodent.

3. The method of claim 1, wherein the one or more biom

12
8. A method of determining whether a compound is effec
tive for ameliorating the symptoms of EAE in a rodent, com
prising:
collecting a first urine sample from a rodent having EAE;
determining the levels of one or more biomarkers in the
first urine sample, wherein the one or more biomarkers
comprise 3-ureidopropionic acid;
administering a compound to the rodent having EAE;
collecting a second urine sample from the rodent having

arkers further comprise guanidinoacetate and indoxyl Sulfate.
25

12. The method of claim 8, wherein the levels of the one or

more biomarkers are determined using an immunoassay,
chromatography, spectroscopy or NMR.
k
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